U.S., May 28 -- ClinicalTrials.gov registry received information related to the study (NCT07608770) titled 'A Study to Evaluate the Efficacy, Safety, and Tolerability of CBL-514 Injection for Reducing Abdominal Subcutaneous Fat' on May 19.
Brief Summary: A phase 2b, randomized, placebo-controlled study with long-term re-treatment to evaluate the efficacy, safety, and tolerability of CBL-514 injection for reducing abdominal subcutaneous fat
Study Start Date: May, 2026
Study Type: INTERVENTIONAL
Condition:
Subcutaneous Fat
Intervention:
DRUG: CBL-514 Injection
Provided as a ready for use injectable CBL-514 solution
DRUG: 0.9% Sodium Chloride
Injectable 0.9% Sodium Chloride solution as placebo
Recruitment Status: NOT_YET_RECRUITING...